Zhitong Financial APP News, * ST eye medicine (600671.SH) notice, the company recently received the China Securities Regulatory Commission Zhejiang Regulatory Bureau ("Zhejiang Securities Regulatory Bureau") issued by the "Hangzhou Tianmushan Pharmaceutical Co., Ltd. and the relevant responsible persons of the decision to issue a warning letter" ("warning letter").
It is reported that Zhejiang Securities Supervision Bureau found the following problems in the supervision of the company: first, the company made a mistake in the presentation of projects under construction from 2020 to 2022 and had the problem of less depreciation. Second, the company fails to disclose the freezing of bank accounts in time. Third, the company failed to disclose in time the progress of bankruptcy liquidation of Zhejiang Tianmu Biotechnology Co., Ltd. ("Tianmu Biology"), a holding subsidiary. Fourth, the disclosure of the relevant information of the company's performance forecast is not accurate. 5. The materials of the company's board of directors are incomplete and some directors have not signed the signature page of the meeting resolution.
The announcement shows that the above problems of the company violate relevant regulations; Li Feng, then chief financial officer and secretary of the board of directors, and Liu Bo, general manager of the company, bear the main responsibility for the above violations. According to the regulations, Zhejiang Securities Regulatory Bureau decided to take supervision and management measures of issuing warning letters to the company, Li Feng and Liu Bo respectively, which were recorded in the integrity files of the securities and futures market.